STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on CEO interviews and corporate events.
LOS ANGELES, Aug. 10, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 405 owned and operated outpatient imaging centers, today reported financial results for its second quarter of 2025.
In a recent video Q&A, board-certified plastic surgeon Dr. Pane breaks down the differences between tummy tuck, revision surgery, and liposuction, helping patients choose...
As more women seek revision or removal of breast implants, Dr. Pane offers safe, personalized solutions with long-term, natural-looking results.
NORTH PALM BEACH, Fla., Aug....
– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant –
Guests can enjoy Chick-fil-A's first-ever seasonal soda, a bold new sandwich and the crunch of new chips
ATLANTA, Aug. 8, 2025 /PRNewswire/ -- Launching August...
NEW YORK, Aug. 8, 2025 /PRNewswire/ -- LILYSILK, the world's leading silk brand dedicated to inspiring people to live spectacular, sustainable lives, proudly marks...
NEW YORK, Aug. 8, 2025 /PRNewswire/ -- LILYSILK, the world's leading silk brand dedicated to inspiring people to live spectacular, sustainable lives, proudly marks...
Dr. Wenham is Principal investigator on Anixa's CAR-T therapy for Ovarian Cancer
SAN JOSE, Calif., Aug. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or...
FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2025, and provide a corporate update on August 14, 2025, at 8:30 a.m. Eastern Time.
TAIPEI and SAN DIEGO, Aug. 7, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for...
AHMEDABAD, India, Aug. 7, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as...